0001021771-24-000140.txt : 20240524 0001021771-24-000140.hdr.sgml : 20240524 20240524164527 ACCESSION NUMBER: 0001021771-24-000140 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240523 ITEM INFORMATION: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review FILED AS OF DATE: 20240524 DATE AS OF CHANGE: 20240524 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioRestorative Therapies, Inc. CENTRAL INDEX KEY: 0001505497 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 301341024 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37603 FILM NUMBER: 24985158 BUSINESS ADDRESS: STREET 1: 40 MARCUS DRIVE CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: (631) 760-8100 MAIL ADDRESS: STREET 1: 40 MARCUS DRIVE CITY: MELVILLE STATE: NY ZIP: 11747 FORMER COMPANY: FORMER CONFORMED NAME: Stem Cell Assurance, Inc. DATE OF NAME CHANGE: 20101110 8-K 1 brt8k523.htm RE: RESTATEMENT

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 23, 2024

BioRestorative Therapies, Inc.
(Exact name of registrant as specified in its charter)

Nevada
 
001-37603
 
30-1341024
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)

40 Marcus Drive
Melville, New York
 
11747
(Address of principal executive offices)
 
(Zip code)

Registrant's telephone number, including area code (631) 760-8100

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value
 BRTX
 NASDAQ Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 4.02
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

(a) On May 23, 2024, BioRestorative Therapies, Inc. (the “Company”), in consultation with its Audit Committee, concluded that its previously issued financial statements (i) as of and for the two years ended December 31, 2023 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “Annual Periods”) and (ii) unaudited interim financial statements for the quarters ended March 31, 2022 through September 30, 2023 included in the Company’s quarterly reports on Form 10-Q for the periods ended March 31, 2023, June 30, 2023 and September 30, 2023 (the “Interim Periods”, which, together with the Annual Periods, the “Affected Periods”) should be restated because of a misapplication in the guidance around the accounting for certain warrants, as discussed below, and should no longer be relied upon.  However, the non-cash adjustments to the financial statements for the Affected Periods do not impact the amounts previously reported for the Company’s cash, cash equivalents and investments held in marketable securities.  In addition, such non-cash adjustments will not impact the amounts previously reported as revenues, operating expenses or loss from operations for the Affected Periods.
The warrants at issue are the following:
(i) the warrants to purchase an aggregate of 2,645,000 shares of the Company’s common stock, issued in November 2021 pursuant to an underwritten public offering, which warrants provide for an exercise price of $10.00 per share (the “Public Warrants”);
(ii) the warrants to purchase an aggregate of 1,856,938 shares of the Company’s common stock, issued in November 2021 pursuant to a private offering, which warrants provide for an exercise price of $10.00 per share (the “Private Warrants”); and
(iii) the warrants to purchase an aggregate of 235,970 shares of the Company’s common stock, issued in November 2021 to the underwriter of the public offering, which warrants provide for an exercise price of $12.50 per share (together with the Public Warrants and the Private Warrants, the “Warrants”).
 Historically, the Warrants were included as a component of stockholders’ equity. It has now been determined, in accordance with Accounting Standards Codification 815, that the Warrants should be included as a component of liabilities on the balance sheets and the statements of operations should include the subsequent non-cash changes in estimated fair value of the Warrants (the “Restatement”).
The Restatement is non-cash in nature and will have no impact on the Company’s cash, cash equivalents and investments held in marketable securities.  In addition, the non-cash adjustments will not impact the amounts previously reported as revenues, operating expenses or loss from operations for the Affected Periods.

The Company currently anticipates filing an amended Annual Report on Form 10-K for the year ended December 31, 2023 (“Amended Form 10-K”), which Amended Form 10-K will reflect the impact of the Restatement for the Affected Periods (for the avoidance of doubt, the impact of the Restatement on the Interim Periods will be summarized in the Amended Form 10-K and the Company does not intend to amend its previously issued Form 10-Qs for such Interim Periods).  The Company will effectuate the restatement of its 2023 unaudited interim financial statements in connection with the future filings of its Quarterly Reports on Form 10-Q in 2024. The Company plans to file the Amended Form 10-K as soon as reasonably practicable and is presently targeting such a filing on or before June 28, 2024. The Company also plans to file its Quarterly Report on Form 10-Q for the period ended March 31, 2024 concurrently with such filing.
The preliminary evaluation provided above is subject to the completion of the Company’s restatement analysis and financial close and reporting process, as well as the financial statement audits and reviews for the Affected Periods.
The Audit Committee has discussed the matters described in this Form 8-K with its independent registered accounting firm, Marcum LLP.

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  BIORESTORATIVE THERAPIES, INC.
  
       
Dated:  May 24, 2024
By:
/s/ Lance Alstodt
  
    Lance Alstodt
  
    Chief Executive Officer
  
       


EX-101.SCH 2 brtx-20240523.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 brtx-20240523_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 4 brtx-20240523_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
May 23, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 23, 2024
Entity File Number 001-37603
Entity Registrant Name BioRestorative Therapies, Inc.
Entity Central Index Key 0001505497
Entity Incorporation, State or Country Code NV
Entity Tax Identification Number 30-1341024
Entity Address, Address Line One 40 Marcus Drive
Entity Address, City or Town Melville
Entity Address, State or Province NY
Entity Address, Postal Zip Code 11747
City Area Code 631
Local Phone Number 760-8100
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol BRTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 22 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://biorestorative.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brt8k523.htm brtx-20240523.xsd brtx-20240523_lab.xml brtx-20240523_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "brt8k523.htm": { "nsprefix": "brtx", "nsuri": "http://biorestorative.com/20240523", "dts": { "inline": { "local": [ "brt8k523.htm" ] }, "schema": { "local": [ "brtx-20240523.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "brtx-20240523_lab.xml" ] }, "presentationLink": { "local": [ "brtx-20240523_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://biorestorative.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240523to20240523", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "brt8k523.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240523to20240523", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "brt8k523.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://biorestorative.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001021771-24-000140-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001021771-24-000140-xbrl.zip M4$L#!!0 ( *N%N%@Z9\;6I18 /AK , 8G)T.&LU,C,N:'1M[5U; M=^,VDG[/K\!J+NT^1Q=>1=)V>X[;[4YKTVT[LK+)[LL>D 0MIBE"0U*6M;]^ MJP"2(B52EF4[G62F'V*)Q*7PH5#U50%03O_Q,(O(/4O2D,?OWJA]Y0UALO./L^].IQD4@Z)Q>OS@)E'XKC/-LOGQ8+!<+OOXI,^3NX&F M*/H@C-.,QA[KY.6C,/ZZHSB^=FE:%G_8*K_416G5<9R!>%L63<.F@M"L.OCE MR^=;;\IFM++=A9I[X[2^?8@\Q>U@?IL ^:B1WA1*^CQ19PE MJ^;"^FFS2.)539XT])J+PHMZP6R>M)2$-[6B[,&;-A?%-W4$6= "'@MJ!=TD M6^NK&_*$I1E/0#_N6=_C,RQK*&99OGWEH@GIG'U'R.F441\_P,9]PZB>A?\?(S?@Z""-&-+VO:GVU;ZKV<%W_ M@L]727@WS0A(;9(>P?%5J_=ZN9@SEE&"@^VQ?R["^W>="QYGT'-O FK4(9[\ M]JZ3L8=L( 8_ $,ZD(/_[M3E_HJDV2IB[SH!E.T%=!9&JV/R9A+.6$JNV)*, M.0SP39>()UV2LB0,3H@HG8;_QXZ)JLRS$X(]] "9N_B81"R )QZ/>'),_J*( M?R?$I=[7NP06DM\K7@7BWPG,R*D?WI/0?]?Y<'OS,40[\"GT?19W"O'\,)U' M%$2+>G:*W.TZ% M'X.FB?!^Q],$>\%UV2O:[S^D?B=_C5;L72<-9_.(@[D8_5 ?_F;EL^)1O?4YH,/]XAOX M\"3[ "OZ#(7J*69/TXMZZW>EF'Y+T>)-\;WH9%##H0"M1&E0T?@!+!=8P& ! M\,.IFPR$4:L]/FAA=W+#4JF_L8[S$GG7I=$ZG29%!9OT/[MY<5/X]%D='E+SJ\^D,M?+CZ=7WU_22ZNOWP9W=Z.KJ\. M[U1KZ_1GFD[!L64<'."'_D4?_!2LKO:.YM1'3E_JPA :[IR10GU%\8.EM-ND M_'@]_D):S6[AJZ7#+*VMYP>VK9J>8=N^85#=,71%"X*A2RV'60K=P]K:O1^V MS>R31U<;S-:TO!AZ2AMZH%;CRZL)&5_>7(\GS^N@KH1KL4VSV^-CYHR0D/R)C- M>9*1H^([HV#+@:82=H],,!&OF?_V^'%5O!'^X%)ZB8I.6J;J*)87^.K0,@S% M<2U- >]O4KW@JD[@'I.OM"5\!-NX)X[J_$ MKZ6=6JO9>X1-C=E=F&(\F5W!FPJ4CF\ZVA"8E!HXAN?:#E44ZC(*O$\S;7T/ MVG?V/N3C=1A")E.6T'F(GG04>_TMT/;"82>KSH'IG!U=/L 8Q&!1TY)RD(2F M))TS#QF-3R!(";.4>%,@)BQY^Y1N-PWU'K.941?B&8]%43JG'F9N.DI'?,\; M$]_S#I>AGTVQ,^5O^T0.SPM-.FN2L@ZQ\.-IEIQ5GN2O3S-_0TP=I;S'^,^C M42&IA&:+WF@E@ZE+WRS/H7[@4<4'%>3)7.@FCV\S6.D7,H-QP?WJ.E"=H>$: MBFOHIFM8.G-TQS1=U56'^I Z3O TDX+9'23"&9LG_!YE0EMRQ>ZI3W9O]7#M M"2.TI33 HFW/MEW-M13#TZGM#DW'TSS%IBHS3&4/I=&5GJH;:A-'.4QK1 Q= M]PK/]1,0U[[ #(#3%U:<\(3P#*@&^761A*D?>H@M:1HN06X05OW V]=:-[_7 M)?)BV%_PV2Q,TW:HT2P2J>+_1OE0E$=C"/=F\XBO0+^;<:[;%'+%^_O O;6L M\P_?P5.DK=6,5@,GMO^5R:]A/B);?B:[AE4MQR/.I3Z%O484S5WGXR.H9 O-/$6*?F00,S7$A@?+/@%?+Q. M)GP95X-^)U"8;P46]14#0E7J@HM4(7A57=^GBK6'V%]8=!]&T9:\W?941$TN MX7FNDQO@]*'8PRZ%

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end XML 16 brt8k523_htm.xml IDEA: XBRL DOCUMENT 0001505497 2024-05-23 2024-05-23 false 0001505497 8-K 2024-05-23 BioRestorative Therapies, Inc. NV 001-37603 30-1341024 40 Marcus Drive Melville NY 11747 631 760-8100 Common Stock, $0.0001 par value BRTX NASDAQ false false false false false